U.S. Wireless Telecom Stock News

NYSE:CAH
NYSE:CAHHealthcare

Should Cardinal Health’s (CAH) Planned CAO Retirement Shape Views on Its Earnings-Focused Strategy?

In early March 2026, Cardinal Health announced that longtime Senior Vice President and Chief Accounting Officer Mary Scherer plans to retire in February 2027, and the company has begun searching for her successor while she stays on to oversee an orderly transition. This carefully staged leadership change in a core finance role comes as Cardinal Health is emphasizing earnings growth, acquisitions and product innovation as key elements of its longer-term plans. Next, we’ll examine how Cardinal...
NYSE:ESI
NYSE:ESIChemicals

How Investors May Respond To Element Solutions (ESI) Margin Jitters From Rising Middle East-Linked Input Costs

Element Solutions recently faced a sector-driven setback as escalating conflict in the Middle East pushed up crude oil and petrochemical feedstock costs, prompting investors to reassess cost pressures across specialty chemical producers. The reaction appears tied more to short-term fears about margin compression from higher inputs than to any shift in Element Solutions’ underlying demand or operations, which remain unchanged. We’ll now examine how concerns over rising input costs and...
NYSE:ELV
NYSE:ELVHealthcare

Elevance Expands Myomo Coverage And Broadens Technology Enabled Care Story

Elevance Health (NYSE:ELV) has signed new network participation agreements with Myomo, Inc. The deals extend in-network coverage for Myomo’s FDA cleared orthopedic devices to Elevance’s roughly 45 million Commercial, Medicare Advantage, and Medicaid members nationwide. For you as an investor, this ties directly into how NYSE:ELV positions itself as a broad based health benefits and services company. Elevance already spans commercial employer plans, government programs, and related health...
NYSE:TPL
NYSE:TPLOil and Gas

A Look At Texas Pacific Land (TPL) Valuation After Dividend Increase And Strong Earnings From Water And Land Segments

Texas Pacific Land (TPL) is back on investors’ radar after the company increased its quarterly dividend to US$0.60 per share and reported strong fourth quarter earnings, supported by its Water Services and Land segments. See our latest analysis for Texas Pacific Land. The share price has moved sharply in recent months, with a 40.14% 1 month share price return and a 76.85% 3 month share price return. The 1 year total shareholder return of 17.53% and 3 year total shareholder return of about 3x...
NasdaqGS:ALGN
NasdaqGS:ALGNMedical Equipment

How SprintRay’s Midas Tour Partnership Shapes Align Technology’s (ALGN) Chairside Digital Dentistry Role

On 11 March 2026, SprintRay announced the launch of its Midas World Tour, a collaboration with Align Technology, GC America and Meisinger Dental to promote an integrated, same-day digital restorative workflow that combines iTero scanning, AI-driven 3D printing, advanced materials and finishing tools. This partnership highlights how Align’s iTero scanners are becoming a core part of chairside restorative dentistry as 3D printing moves toward an integrated workflow standard in dental...
NYSE:PATH
NYSE:PATHSoftware

Assessing UiPath (PATH) Valuation After Recent Share Price Rebound And Mixed Performance

Context for UiPath after recent share moves UiPath (PATH) has seen its share price move sharply in recent trading, with a 6.8% gain over the past day and 11.8% over the past week, even as returns over the past month and past 3 months remain negative. That mix of short term strength alongside weaker recent performance is prompting some investors to reassess how the company’s US$1,553.1m in annual revenue and US$229.7m in net income line up against current market expectations for the automation...
NYSE:SNDR
NYSE:SNDRTransportation

Is Citigroup’s Neutral Call Reframing Schneider National’s (SNDR) Earnings Reliability Narrative in Freight Logistics?

Earlier this week, Citigroup’s Ariel Rosa shifted Schneider National’s rating from “Sell” to “Neutral,” citing mixed financial indicators, earnings volatility, and broad sector headwinds, while acknowledging the company’s diversified operations across truckload and intermodal freight. This change in analyst stance, following a period of subdued revenue growth and falling earnings per share, spotlights how Schneider’s business mix and perceived earnings reliability are becoming central to how...
NasdaqGS:CSCO
NasdaqGS:CSCOCommunications

A Look At Cisco Systems (CSCO) Valuation After Margin Concerns Weigh On Post Earnings Reaction

Cisco Systems (CSCO) has come under pressure after its latest earnings, as concerns about lower gross margins, rising memory costs, and a hardware heavy mix outweighed solid order growth and headline beats. See our latest analysis for Cisco Systems. The share price reaction around earnings fits into a mixed pattern, with a 10% 30 day share price decline and a 3.4% 7 day pullback, offset by a stronger 32.3% 1 year total shareholder return. This suggests that shorter term momentum is fading...
NYSE:GBTG
NYSE:GBTGHospitality

Global Business Travel Group’s Transformation Raises Questions On Value And Execution

Global Business Travel Group (NYSE:GBTG) has completed its acquisition of CWT, reaching what management calls an inflection point in its business transformation. The company is rolling out Egencia AI, which management says is already contributing to measurable revenue and cost efficiencies. GBTG reports strong revenue growth and profitability in 2025 alongside accelerated integration, restructuring, and productivity efforts. For investors watching NYSE:GBTG, the share price at $5.57 sits...
NasdaqGS:JAZZ
NasdaqGS:JAZZPharmaceuticals

A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Record Revenue And Supportive Barclays Commentary

Recent commentary from Barclays on Jazz Pharmaceuticals (JAZZ) has put fresh attention on the stock, after the bank highlighted the durability of its central nervous system therapies and record fourth quarter revenue tied to Xywav, Epidiolex, and Modeyso. See our latest analysis for Jazz Pharmaceuticals. At a share price of US$185.43, Jazz has given investors a 12.38% 1 month share price return and a 38.22% 1 year total shareholder return. This suggests that recent revenue headlines and...
NasdaqGS:CIFR
NasdaqGS:CIFRSoftware

Cipher Digital (CIFR) Valuation Check As AI Infrastructure Pivot And Short Interest Drive Volatility

What is driving Cipher Digital’s recent stock volatility? Cipher Digital (CIFR) is in focus after shifting its business toward high performance computing and AI infrastructure, supported by partnerships with large tech firms, asset sales, and fresh acquisitions. This repositioning, combined with elevated short interest and mixed analyst views, has contributed to the recent volatility that investors are now trying to interpret. See our latest analysis for Cipher Digital. At a share price of...
NYSE:RIG
NYSE:RIGEnergy Services

Transocean Valaris Merger Reshapes Offshore Fleet Scale And Valuation Story

Transocean has completed an all stock acquisition of Valaris, combining two major offshore drilling companies. The deal significantly expands Transocean's offshore rig fleet and contract portfolio. Management expects cost synergies and a stronger competitive position in the global offshore drilling market. For investors watching NYSE:RIG, this merger follows a period of strong share price moves, with the stock up 48.8% year to date and 111.7% over the past year, closing at $6.31. The...
NasdaqGS:PLPC
NasdaqGS:PLPCElectrical

Is It Too Late To Consider Preformed Line Products (PLPC) After A 118% One-Year Rally?

If you are wondering whether Preformed Line Products is still offering value after a strong run, this article walks through what the current share price might be implying about the business. The stock closed at US$267.23 recently, with returns of 4.6% over 7 days, a 2.5% decline over 30 days, 26.1% year to date and 118.3% over the past year, as well as 135.3% over 3 years and 271.3% over 5 years. Recent attention on grid reliability, utility infrastructure and related capital projects has...
NasdaqGS:DPZ
NasdaqGS:DPZHospitality

Is Domino's Pizza (DPZ) Fairly Valued After Recent Share Price Weakness?

If you are wondering whether Domino's Pizza shares are priced attractively today, the key question is how the current market price compares with the company's underlying value. The stock recently closed at US$393.29, with returns of a 3.3% decline over 7 days, 0.3% over 30 days, a 7.5% decline year to date and an 8.9% decline over the past year, while the 3 year and 5 year returns sit at 30.8% and 15.0% respectively. Recent company news has focused on Domino's ongoing efforts to refine its...
NYSE:WFC
NYSE:WFCBanks

Wells Fargo Trademark WFUSD Signals New Crypto Services And Investor Questions

Wells Fargo has filed a trademark application for "WFUSD," indicating potential plans to offer digital asset and cryptocurrency services. The filing points to possible products such as crypto trading, exchange services, payment processing, and digital asset wallets. This move would represent an expansion of Wells Fargo's role in the growing crypto and blockchain segment of financial services. Shares of Wells Fargo (NYSE:WFC) last closed at $76.88, with the stock showing a 14.0% return over...
NasdaqCM:LTRX
NasdaqCM:LTRXCommunications

Lantronix (LTRX) Valuation Check After MediaTek Edge AI Expansion And Melchioni Distribution Deal

Lantronix (LTRX) is back on investor radars after expanding its embedded compute portfolio with new MediaTek based System on Module solutions and signing a European distribution deal with Melchioni Electronics. See our latest analysis for Lantronix. The recent MediaTek based SOM launch and the Melchioni distribution deal arrive after a mixed stretch for the stock, with a 7 day share price return of 3.89% but a 90 day share price return decline of 6.69%, while the 1 year total shareholder...
NasdaqGS:QURE
NasdaqGS:QUREBiotechs

UniQure Faces AMT-130 Scrutiny As FDA Shifts And Lawsuits Weigh

uniQure (NasdaqGS:QURE) faces multiple securities class action lawsuits focused on disclosures around its AMT-130 gene therapy program. Federal health officials have criticized the company for alleged data manipulation tied to AMT-130. The FDA has withdrawn support for a Biologics License Application for AMT-130, complicating the program's regulatory path. Upcoming changes in FDA leadership are expected to affect how AMT-130 and related filings are reviewed. These developments arrive at a...
NasdaqGS:VIAV
NasdaqGS:VIAVCommunications

Is It Too Late To Consider Viavi Solutions (VIAV) After A 180% One Year Surge?

If you are wondering whether Viavi Solutions is still fairly priced after a big run, this breakdown will help you see how the current share price stacks up against several valuation yardsticks. The stock last closed at US$30.09, with returns of 8.9% over the past 30 days and 65.8% year to date, while the 1 year return sits at 179.6% and the 3 year return at 193.3%. Over the past year, Viavi Solutions has been in the news for its position in optical networking and communications testing. This...
NasdaqGS:CRWD
NasdaqGS:CRWDSoftware

CrowdStrike Extends Falcon Into AI Browsers With Perplexity Partnership

CrowdStrike Holdings (NasdaqGS:CRWD) announced a new partnership with Perplexity to bring its Falcon platform into Perplexity’s Comet Enterprise product. The collaboration focuses on browser-layer security for AI-powered enterprise workflows and AI-native browsing. The deal uses technology from CrowdStrike’s Seraphic acquisition to address web threats and unmanaged devices. CrowdStrike is best known for its Falcon cybersecurity platform, which targets endpoint, cloud, and identity threats...
NasdaqGS:DOX
NasdaqGS:DOXIT

Is It Time To Reconsider Amdocs (DOX) After A 22% Share Price Slide?

If you are wondering whether Amdocs is starting to look like value after a weaker share price, this article will help you weigh what the current price actually offers you. The stock last closed at US$66.92, with returns of a 2.6% decline over 7 days, an 8.8% decline over 30 days, a 16.5% decline year to date, and a 21.6% decline over the past year. Recent coverage around Amdocs has focused on its role as a software and services provider to telecom and media companies. This keeps attention on...
NasdaqGS:DAWN
NasdaqGS:DAWNBiotechs

Servier All Cash Deal Reframes Day One Biopharmaceuticals Valuation Story

Servier Pharmaceuticals has entered into a definitive agreement to acquire Day One Biopharmaceuticals, NasdaqGS:DAWN, in an all cash transaction. The deal marks a material change in ownership, bringing Day One Biopharmaceuticals under Servier control and ending its status as an independent company once the transaction closes. Day One Biopharmaceuticals focuses on developing and commercializing oncology therapies, a segment that has seen frequent partnerships, licensing arrangements, and...
NYSE:LYV
NYSE:LYVEntertainment

Is Live Nation Entertainment (LYV) Pricing In Too Much Optimism After Its Strong Multi‑Year Rally

If you are wondering whether Live Nation Entertainment's share price still reflects fair value after a strong run, you are not alone. This article will walk through what the current price could imply. The stock recently closed at US$165.83, with returns of 4.5% over the last 7 days, 12.1% over the last 30 days, 14.1% year to date, 34.9% over 1 year, 147.4% over 3 years and 91.3% over 5 years. These figures may prompt questions about how much of the story is already in the price. Recent...
NasdaqGS:STRL
NasdaqGS:STRLConstruction

A Look At Sterling Infrastructure (STRL) Valuation After Conference Spotlight And Free Cash Flow Strength

Sterling Infrastructure (STRL) is back in focus as management prepares to present at the 2026 Cantor Global Technology & Industrial Growth Conference in New York, highlighting projects such as Houston’s Grand Parkway and recent free cash flow strength. See our latest analysis for Sterling Infrastructure. The upcoming conference appearance comes after a sharp upswing in Sterling Infrastructure’s share price, with a 23.5% 90 day share price return and a very large 5 year total shareholder...
NYSE:AHR
NYSE:AHRHealth Care REITs

A Look At American Healthcare REIT's Valuation As Profitability Rebounds And Guidance Signals Further Growth

Earnings turnaround and fresh guidance draw investor focus American Healthcare REIT (AHR) has quickly come onto investors’ radar after reporting a shift from loss to profit for 2025, pairing that earnings turnaround with new guidance and an at the market equity program. See our latest analysis for American Healthcare REIT. That earnings swing to profit and fresh 2026 guidance have come alongside firm price momentum, with an 11.8% year to date share price return and a very strong 1 year total...